- Report
- February 2024
- 198 Pages
Global
From €3428EUR$3,600USD£2,930GBP
- Report
- November 2023
- 630 Pages
Global
From €9045EUR$9,500USD£7,731GBP
- Report
- January 2022
- 200 Pages
Global
From €7141EUR$7,500USD£6,104GBP
- Clinical Trials
- September 2020
- 75 Pages
Global
From €1904EUR$2,000USD£1,628GBP
- Report
- April 2019
- 93 Pages
Global
From €3094EUR$3,250USD£2,645GBP
- Report
- August 2018
- 16 Pages
Global
From €9521EUR$10,000USD£8,138GBP
- Report
- August 2018
- 22 Pages
Global
From €9521EUR$10,000USD£8,138GBP
- Report
- August 2018
- 16 Pages
Global
From €9521EUR$10,000USD£8,138GBP
- Report
- April 2021
- 191 Pages
Global
€20946EUR$22,000USD£17,904GBP
- Report
- August 2018
- 19 Pages
Global
From €9521EUR$10,000USD£8,138GBP
Xalkori (crizotinib) is a targeted therapy drug used to treat non-small cell lung cancer (NSCLC). It is a tyrosine kinase inhibitor (TKI) that works by blocking the activity of a protein called anaplastic lymphoma kinase (ALK). This protein is found in some types of NSCLC and is associated with tumor growth. Xalkori is approved by the US Food and Drug Administration (FDA) for the treatment of metastatic NSCLC with ALK-positive tumors. It is also approved for the treatment of ROS1-positive NSCLC.
Xalkori is a key drug in the lung cancer market, as it is the only approved therapy for ALK-positive NSCLC. It is also the only approved therapy for ROS1-positive NSCLC. Xalkori is a well-established drug, with a long history of clinical trials and a strong safety profile.
The Xalkori market is highly competitive, with several major pharmaceutical companies competing for market share. These include Pfizer, Merck, AstraZeneca, and Novartis. Other companies, such as Boehringer Ingelheim, Daiichi Sankyo, and Eli Lilly, also have a presence in the market. Show Less Read more